3.69
+0.28(+8.21%)
Currency In USD
| Previous Close | 3.41 |
| Open | 3.45 |
| Day High | 3.72 |
| Day Low | 3.44 |
| 52-Week High | 10.72 |
| 52-Week Low | 1.78 |
| Volume | 1.08M |
| Average Volume | 1.97M |
| Market Cap | 636.2M |
| PE | -1.93 |
| EPS | -1.91 |
| Moving Average 50 Days | 3.49 |
| Moving Average 200 Days | 3.75 |
| Change | 0.28 |
If you invested $1000 in Relay Therapeutics, Inc. (RLAY) since IPO date, it would be worth $105.28 as of August 24, 2025 at a share price of $3.69. Whereas If you bought $1000 worth of Relay Therapeutics, Inc. (RLAY) shares 3 years ago, it would be worth $141.38 as of August 24, 2025 at a share price of $3.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies,
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
GlobeNewswire Inc.
Jun 11, 2025 8:05 PM GMT
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies,
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
GlobeNewswire Inc.
Jun 02, 2025 11:00 AM GMT
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Nex